Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Autonomic Research
Erschienen in: Clinical Autonomic Research 2/2021

14.09.2020 | Review

Sympathetic and parasympathetic innervation in cancer: therapeutic implications

verfasst von: Atsunori Kamiya, Takeshi Hiyama, Atsushi Fujimura, Soichiro Yoshikawa

Erschienen in: Clinical Autonomic Research | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The autonomic nervous system, consisting of sympathetic and parasympathetic/vagal nerves, is known to control the functions of any organ, maintaining whole-body homeostasis under physiological conditions. Recently, there has been increasing evidence linking sympathetic and parasympathetic/vagal nerves to cancers. The present review aimed to summarize recent developments from studies addressing the relationship between sympathetic and parasympathetic/vagal nerves and cancer behavior.

Methods

Literature review.

Results

Human and animal studies have revealed that sympathetic and parasympathetic/vagal nerves innervate the cancer microenvironment and alter cancer behavior. The sympathetic nerves have cancer-promoting effects on prostate cancer, breast cancer, and melanoma. On the other hand, while the parasympathetic/vagal nerves have cancer-promoting effects on prostate, gastric, and colorectal cancers, they have cancer-suppressing effects on breast and pancreatic cancers. These neural effects may be mediated by β-adrenergic or muscarinic receptors and can be explained by changes in cancer cell behavior, angiogenesis, tumor-associated macrophages, and adaptive antitumor immunity.

Conclusions

Sympathetic nerves innervating the tumor microenvironment promote cancer progression and are related to stress-induced cancer behavior. The parasympathetic/vagal nerves have variable (promoting or suppressing) effects on different cancer types. Approaches directed toward the sympathetic and parasympathetic/vagal nerves can be developed as a new cancer therapy. In addition to existing pharmacological, surgical, and electrical approaches, a recently developed virus vector-based genetic local neuroengineering technology is a powerful approach that selectively manipulates specific types of nerve fibers innervating the cancer microenvironment and leads to the suppression of cancer progression. This technology will enable the creation of "cancer neural therapy" individually tailored to different cancer types.
Literatur
1.
Kamiya A, Hayama Y, Kato S, Shimomura A, Shimomura T, Irie K, Kaneko R, Yanagawa Y, Kobayashi K, Ochiya T (2019) Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression. Nat Neurosci 22:1289–1305PubMedCrossRef
2.
Karemaker JM (2017) An introduction into autonomic nervous function. Physiol Meas 38:R89–R118PubMedCrossRef
3.
Wehrwein EA, Orer HS, Barman SM (2016) Overview of the anatomy, physiology, and pharmacology of the autonomic nervous system. Compr Physiol 6:1239–1278PubMedCrossRef
4.
Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AK (2015) Sympathetic nervous system regulation of the tumour microenvironment. Nat Rev Cancer 15:563–572PubMedPubMedCentralCrossRef
5.
6.
7.
Faulkner S, Jobling P, March B, Jiang CC, Hondermarck H (2019) Tumor neurobiology and the war of nerves in cancer. Cancer Discov 9:702–710PubMedCrossRef
8.
Hondermarck H, Jobling P (2018) The sympathetic nervous system drives tumor angiogenesis. Trends Cancer 4:93–94PubMedCrossRef
9.
10.
Zahalka AH, Arnal-Estape A, Maryanovich M, Nakahara F, Cruz CD, Finley LWS, Frenette PS (2017) Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science 358:321–326PubMedPubMedCentralCrossRef
11.
Lucas D, Scheiermann C, Chow A, Kunisaki Y, Bruns I, Barrick C, Tessarollo L, Frenette PS (2013) Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. Nat Med 19:695–703PubMedPubMedCentralCrossRef
12.
Simo M, Navarro X, Yuste VJ, Bruna J (2018) Autonomic nervous system and cancer. Clin Auton Res 28:301–314PubMedCrossRef
13.
Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, Frenette PS (2013) Autonomic nerve development contributes to prostate cancer progression. Science 341:1236361CrossRefPubMed
14.
Bae GE, Kim HS, Won KY, Kim GY, Sung JY, Lim SJ (2019) Lower Sympathetic nervous system density and beta-adrenoreceptor expression are involved in gastric cancer progression. Anticancer Res 39:231–236PubMedCrossRef
15.
Zhao CM, Hayakawa Y, Kodama Y, Muthupalani S, Westphalen CB, Andersen GT, Flatberg A, Johannessen H, Friedman RA, Renz BW, Sandvik AK, Beisvag V, Tomita H, Hara A, Quante M, Li Z, Gershon MD, Kaneko K, Fox JG, Wang TC, Chen D (2014) Denervation suppresses gastric tumorigenesis. Sci Transl Med 6:250ra115PubMedPubMedCentralCrossRef
16.
Zhou H, Shi B, Jia Y, Qiu G, Yang W, Li J, Zhao Z, Lv J, Zhang Y, Li Z (2018) Expression and significance of autonomic nerves and alpha9 nicotinic acetylcholine receptor in colorectal cancer. Mol Med Rep 17:8423–8431PubMed
17.
Zhang L, Wu LL, Huan HB, Chen XJ, Wen XD, Yang DP, Xia F (2017) Sympathetic and parasympathetic innervation in hepatocellular carcinoma. Neoplasma 64:840–846PubMedCrossRef
18.
Bastos DB, Sarafim-Silva BAM, Sundefeld M, Ribeiro AA, Brandao JDP, Biasoli ER, Miyahara GI, Casarini DE, Bernabe DG (2018) Circulating catecholamines are associated with biobehavioral factors and anxiety symptoms in head and neck cancer patients. PLoS ONE 13:e0202515PubMedPubMedCentralCrossRef
19.
Wang L, Zhi X, Zhang Q, Wei S, Li Z, Zhou J, Jiang J, Zhu Y, Yang L, Xu H, Xu Z (2016) Muscarinic receptor M3 mediates cell proliferation induced by acetylcholine and contributes to apoptosis in gastric cancer. Tumour Biol 37:2105–2117PubMedCrossRef
20.
Ciurea RN, Rogoveanu I, Pirici D, Tartea GC, Streba CT, Florescu C, Catalin B, Puiu I, Tartea EA, Vere CC (2017) B2 adrenergic receptors and morphological changes of the enteric nervous system in colorectal adenocarcinoma. World J Gastroenterol 23:1250–1261PubMedPubMedCentralCrossRef
21.
Hayakawa Y, Sakitani K, Konishi M, Asfaha S, Niikura R, Tomita H, Renz BW, Tailor Y, Macchini M, Middelhoff M, Jiang Z, Tanaka T, Dubeykovskaya ZA, Kim W, Chen X, Urbanska AM, Nagar K, Westphalen CB, Quante M, Lin CS, Gershon MD, Hara A, Zhao CM, Chen D, Worthley DL, Koike K, Wang TC (2017) Nerve growth factor promotes gastric tumorigenesis through aberrant cholinergic signaling. Cancer Cell 31:21–34CrossRefPubMed
22.
Stopczynski RE, Normolle DP, Hartman DJ, Ying H, DeBerry JJ, Bielefeldt K, Rhim AD, DePinho RA, Albers KM, Davis BM (2014) Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma. Cancer Res 74:1718–1727PubMedPubMedCentralCrossRef
23.
Fernandez EV, Price DK, Figg WD (2013) Prostate cancer progression attributed to autonomic nerve development: potential for therapeutic prevention of localized and metastatic disease. Cancer Biol Ther 14:1005–1006PubMedPubMedCentralCrossRef
24.
Campbell JP, Karolak MR, Ma Y, Perrien DS, Masood-Campbell SK, Penner NL, Munoz SA, Zijlstra A, Yang X, Sterling JA, Elefteriou F (2012) Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol 10:e1001363PubMedPubMedCentralCrossRef
25.
Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, Sood AK, Cole SW (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70:7042–7052PubMedPubMedCentralCrossRef
26.
Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, Liu H, Kokolus KM, Eng JW, Messmer MN, Attwood K, Abrams SI, Hylander BL, Repasky EA (2017) beta-Adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8+ T cells and undermines checkpoint inhibitor therapy. Cancer Res 77:5639–5651PubMedPubMedCentralCrossRef
27.
Mulcrone PL, Campbell JP, Clement-Demange L, Anbinder AL, Merkel AR, Brekken RA, Sterling JA, Elefteriou F (2017) Skeletal colonization by breast cancer cells is stimulated by an osteoblast and beta2AR-dependent neo-angiogenic switch. J Bone Miner Res 32:1442–1454PubMedCrossRef
28.
Clement-Demange L, Mulcrone PL, Tabarestani TQ, Sterling JA, Elefteriou F (2018) beta2ARs stimulation in osteoblasts promotes breast cancer cell adhesion to bone marrow endothelial cells in an IL-1beta and selectin-dependent manner. J Bone Oncol 13:1–10PubMedPubMedCentralCrossRef
29.
Horvathova L, Tillinger A, Padova A, Mravec B (2016) Sympathectomized tumor-bearing mice survive longer but develop bigger melanomas. Endocr Regul 50:207–214PubMedCrossRef
30.
Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12:939–944PubMedCrossRef
31.
Schuller HM, Al-Wadei HA, Ullah MF, Plummer HK 3rd (2011) Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention. Carcinogenesis 33:191–196PubMedPubMedCentralCrossRef
32.
Powell ND, Tarr AJ, Sheridan JF (2012) Psychosocial stress and inflammation in cancer. Brain Behav Immun 30(Suppl):S41–47PubMed
33.
Reiche EM, Nunes SO, Morimoto HK (2004) Stress, depression, the immune system, and cancer. Lancet Oncol 5:617–625PubMedCrossRef
34.
Bortolato B, Hyphantis TN, Valpione S, Perini G, Maes M, Morris G, Kubera M, Kohler CA, Fernandes BS, Stubbs B, Pavlidis N, Carvalho AF (2017) Depression in cancer: the many biobehavioral pathways driving tumor progression. Cancer Treat Rev 52:58–70PubMedCrossRef
35.
Chida Y, Hamer M, Wardle J, Steptoe A (2008) Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol 5:466–475PubMedCrossRef
36.
Stagl JM, Bouchard LC, Lechner SC, Blomberg BB, Gudenkauf LM, Jutagir DR, Gluck S, Derhagopian RP, Carver CS, Antoni MH (2015) Long-term psychological benefits of cognitive-behavioral stress management for women with breast cancer: 11-year follow-up of a randomized controlled trial. Cancer 121:1873–1881PubMedCrossRef
37.
Stagl JM, Lechner SC, Carver CS, Bouchard LC, Gudenkauf LM, Jutagir DR, Diaz A, Yu Q, Blomberg BB, Ironson G, Gluck S, Antoni MH (2015) A randomized controlled trial of cognitive-behavioral stress management in breast cancer: survival and recurrence at 11-year follow-up. Breast Cancer Res Treat 154:319–328PubMedPubMedCentralCrossRef
38.
Andersen BL, Thornton LM, Shapiro CL, Farrar WB, Mundy BL, Yang HC, Carson WE 3rd (2010) Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants. Clin Cancer Res 16:3270–3278PubMedPubMedCentralCrossRef
39.
Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, Cole SW (2018) Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. Cancer 124:580–586PubMedCrossRef
40.
Grytli HH, Fagerland MW, Fossa SD, Tasken KA (2013) Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 65:635–641PubMedCrossRef
41.
Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 29:2635–2644PubMedCrossRef
42.
Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29:2645–2652PubMedPubMedCentralCrossRef
43.
Montoya A, Amaya CN, Belmont A, Diab N, Trevino R, Villanueva G, Rains S, Sanchez LA, Badri N, Otoukesh S, Khammanivong A, Liss D, Baca ST, Aguilera RJ, Dickerson EB, Torabi A, Dwivedi AK, Abbas A, Chambers K, Bryan BA, Nahleh Z (2017) Use of non-selective beta-blockers is associated with decreased tumor proliferative indices in early stage breast cancer. Oncotarget 8:6446–6460PubMedCrossRef
44.
Childers WK, Hollenbeak CS, Cheriyath P (2015) beta-blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clin Breast Cancer 15:426–431PubMedCrossRef
45.
Raimondi S, Botteri E, Munzone E, Cipolla C, Rotmensz N, DeCensi A, Gandini S (2016) Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: systematic review and meta-analysis. Int J Cancer 139:212–219PubMedCrossRef
46.
Zhao Y, Wang Q, Zhao X, Meng H, Yu J (2017) Effect of antihypertensive drugs on breast cancer risk in female hypertensive patients: evidence from observational studies. Clin Exp Hypertens 40:22–27PubMedCrossRef
47.
Shaashua L, Shabat-Simon M, Haldar R, Matzner P, Zmora O, Shabtai M, Sharon E, Allweis T, Barshack I, Hayman L, Arevalo J, Ma J, Horowitz M, Cole S, Ben-Eliyahu S (2017) Perioperative COX-2 and beta-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a Phase-II Randomized Trial. Clin Cancer Res 23:4651–4661PubMedPubMedCentralCrossRef
48.
Hiller JG, Cole SW, Crone EM, Byrne DJ, Shackleford DM, Pang JB, Henderson MA, Nightingale SS, Ho KM, Myles PS, Fox S, Riedel B, Sloan EK (2019) Preoperative beta-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a Phase II Randomized Trial. Clin Cancer Res 8:1803
49.
De Giorgi V, Grazzini M, Benemei S, Marchionni N, Botteri E, Pennacchioli E, Geppetti P, Gandini S (2017) Propranolol for off-label treatment of patients with melanoma: results from a cohort study. JAMA Oncol 4:e172908PubMedCentralCrossRef
50.
Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW (2020) Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv 4:467–476PubMedPubMedCentralCrossRef
51.
Jang HI, Lim SH, Lee YY, Kim TJ, Choi CH, Lee JW, Kim BG, Bae DS (2017) Perioperative administration of propranolol to women undergoing ovarian cancer surgery: a pilot study. Obstet Gynecol Sci 60:170–177PubMedPubMedCentralCrossRef
52.
Yin QQ, Xu LH, Zhang M, Xu C (2018) Muscarinic acetylcholine receptor M1 mediates prostate cancer cell migration and invasion through hedgehog signaling. Asian J Androl 20:608–614PubMedPubMedCentralCrossRef
53.
Cheng K, Shang AC, Drachenberg CB, Zhan M, Raufman JP (2017) Differential expression of M3 muscarinic receptors in progressive colon neoplasia and metastasis. Oncotarget 8:21106–21114PubMedPubMedCentralCrossRef
54.
Yu H, Xia H, Tang Q, Xu H, Wei G, Chen Y, Dai X, Gong Q, Bi F (2017) Acetylcholine acts through M3 muscarinic receptor to activate the EGFR signaling and promotes gastric cancer cell proliferation. Sci Rep 7:40802PubMedPubMedCentralCrossRef
55.
Raufman JP, Shant J, Xie G, Cheng K, Gao XM, Shiu B, Shah N, Drachenberg CB, Heath J, Wess J, Khurana S (2011) Muscarinic receptor subtype-3 gene ablation and scopolamine butylbromide treatment attenuate small intestinal neoplasia in Apcmin/+ mice. Carcinogenesis 32:1396–1402PubMedPubMedCentralCrossRef
56.
Peng Z, Heath J, Drachenberg C, Raufman JP, Xie G (2013) Cholinergic muscarinic receptor activation augments murine intestinal epithelial cell proliferation and tumorigenesis. BMC Cancer 13:204PubMedPubMedCentralCrossRef
57.
Cheng K, Xie G, Khurana S, Heath J, Drachenberg CB, Timmons J, Shah N, Raufman JP (2014) Divergent effects of muscarinic receptor subtype gene ablation on murine colon tumorigenesis reveals association of M3R and zinc finger protein 277 expression in colon neoplasia. Mol Cancer 13:77PubMedPubMedCentralCrossRef
58.
Erin N, Barkan GA, Clawson GA (2013) Vagus nerve regulates breast cancer metastasis to the adrenal gland. Anticancer Res 33:3675–3682PubMed
59.
Giese-Davis J, Wilhelm FH, Tamagawa R, Palesh O, Neri E, Taylor CB, Kraemer HC, Spiegel D (2015) Higher vagal activity as related to survival in patients with advanced breast cancer: an analysis of autonomic dysregulation. Psychosom Med 77:346–355PubMedPubMedCentralCrossRef
60.
Vigo C, Gatzemeier W, Sala R, Malacarne M, Santoro A, Pagani M, Lucini D (2015) Evidence of altered autonomic cardiac regulation in breast cancer survivors. J Cancer Surviv 9:699–706PubMedCrossRef
61.
Renz BW, Tanaka T, Sunagawa M, Takahashi R, Jiang Z, Macchini M, Dantes Z, Valenti G, White RA, Middelhoff MA, Ilmer M, Oberstein PE, Angele MK, Deng H, Hayakawa Y, Westphalen CB, Werner J, Remotti H, Reichert M, Tailor YH, Nagar K, Friedman RA, Iuga AC, Olive KP, Wang TC (2018) Cholinergic signaling via muscarinic receptors directly and indirectly suppresses pancreatic tumorigenesis and cancer stemness. Cancer Discov 8:1458–1473PubMedPubMedCentralCrossRef
62.
De Couck M, Marechal R, Moorthamers S, Van Laethem JL, Gidron Y (2016) Vagal nerve activity predicts overall survival in metastatic pancreatic cancer, mediated by inflammation. Cancer Epidemiol 40:47–51PubMedCrossRef
63.
Tolaymat M, Larabee SM, Hu S, Xie G, Raufman JP (2019) The role of M3 muscarinic receptor ligand-induced kinase signaling in colon cancer progression. Cancers (Basel) 11:308CrossRef
64.
Austin M, Elliott L, Nicolaou N, Grabowska A, Hulse RP (2017) Breast cancer induced nociceptor aberrant growth and collateral sensory axonal branching. Oncotarget 8:76606–76621PubMedPubMedCentralCrossRef
65.
Bloom AP, Jimenez-Andrade JM, Taylor RN, Castaneda-Corral G, Kaczmarska MJ, Freeman KT, Coughlin KA, Ghilardi JR, Kuskowski MA, Mantyh PW (2011) Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers. J Pain 12:698–711PubMedPubMedCentralCrossRef
66.
Erin N, Zhao W, Bylander J, Chase G, Clawson G (2006) Capsaicin-induced inactivation of sensory neurons promotes a more aggressive gene expression phenotype in breast cancer cells. Breast Cancer Res Treat 99:351–364PubMedCrossRef
67.
Erin N (2020) Role of sensory neurons, neuroimmune pathways, and transient receptor potential vanilloid 1 (TRPV1) channels in a murine model of breast cancer metastasis. Cancer Immunol Immunother 69:307–314PubMedCrossRef
68.
Keskinov AA, Tapias V, Watkins SC, Ma Y, Shurin MR, Shurin GV (2016) Impact of the sensory neurons on melanoma growth in vivo. PLoS ONE 11:e0156095PubMedPubMedCentralCrossRef
69.
Saloman JL, Albers KM, Li D, Hartman DJ, Crawford HC, Muha EA, Rhim AD, Davis BM (2016) Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of cancer. Proc Natl Acad Sci U S A 113:3078–3083PubMedPubMedCentralCrossRef
70.
Sinha S, Fu YY, Grimont A, Ketcham M, Lafaro K, Saglimbeni JA, Askan G, Bailey JM, Melchor JP, Zhong Y, Joo MG, Grbovic-Huezo O, Yang IH, Basturk O, Baker L, Park Y, Kurtz RC, Tuveson D, Leach SD, Pasricha PJ (2017) PanIN neuroendocrine cells promote tumorigenesis via neuronal cross-talk. Cancer Res 77:1868–1879PubMedPubMedCentralCrossRef
71.
Jurcak NR, Rucki AA, Muth S, Thompson E, Sharma R, Ding D, Zhu Q, Eshleman JR, Anders RA, Jaffee EM, Fujiwara K, Zheng L (2019) Axon guidance molecules promote perineural invasion and metastasis of orthotopic pancreatic tumors in mice. Gastroenterology 157(838–850):e836
72.
Hirth M, Gandla J, Hoper C, Gaida MM, Agarwal N, Simonetti M, Demir A, Xie Y, Weiss C, Michalski CW, Hackert T, Ebert MP, Kuner R (2020) CXCL10 and CCL21 promote migration of pancreatic cancer cells toward sensory neurons and neural remodeling in tumors in mice, associated with pain in patients. Gastroenterology 159:665PubMedCrossRef
73.
Peterson SC, Eberl M, Vagnozzi AN, Belkadi A, Veniaminova NA, Verhaegen ME, Bichakjian CK, Ward NL, Dlugosz AA, Wong SY (2015) Basal cell carcinoma preferentially arises from stem cells within hair follicle and mechanosensory niches. Cell Stem Cell 16:400–412PubMedPubMedCentralCrossRef
74.
Amit M, Takahashi H, Dragomir MP, Lindemann A, Gleber-Netto FO, Pickering CR, Anfossi S, Osman AA, Cai Y, Wang R, Knutsen E, Shimizu M, Ivan C, Rao X, Wang J, Silverman DA, Tam S, Zhao M, Caulin C, Zinger A, Tasciotti E, Dougherty PM, El-Naggar A, Calin GA, Myers JN (2020) Loss of p53 drives neuron reprogramming in head and neck cancer. Nature 578:449–454CrossRefPubMed
75.
Reijmen E, Vannucci L, De Couck M, De Greve J, Gidron Y (2018) Therapeutic potential of the vagus nerve in cancer. Immunol Lett 202:38–43PubMedCrossRef
76.
Cardwell CR, Pottegard A, Vaes E, Garmo H, Murray LJ, Brown C, Vissers PA, O'Rorke M, Visvanathan K, Cronin-Fenton D, De Schutter H, Lambe M, Powe DG, van Herk-Sukel MP, Gavin A, Friis S, Sharp L, Bennett K (2016) Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts. Breast Cancer Res 18:119PubMedPubMedCentralCrossRef
77.
Sorensen GV, Ganz PA, Cole SW, Pedersen LA, Sorensen HT, Cronin-Fenton DP, Garne JP, Christiansen PM, Lash TL, Ahern TP (2013) Use of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol 31:2265–2272PubMedPubMedCentralCrossRef
78.
McCourt C, Coleman HG, Murray LJ, Cantwell MM, Dolan O, Powe DG, Cardwell CR (2014) Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study. Br J Dermatol 170:930–938PubMedCrossRef
79.
Hicks BM, Murray LJ, Powe DG, Hughes CM, Cardwell CR (2013) beta-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort. Ann Oncol 24:3100–3106PubMedCrossRef
80.
Irie K, Kitagawa K, Nagura H, Imai T, Shimomura T, Fujiyoshi Y (2009) Comparative study of the gating motif and C-type inactivation in prokaryotic voltage-gated sodium channels. J Biol Chem 285:3685–3694PubMedPubMedCentralCrossRef
Metadaten
Titel
Sympathetic and parasympathetic innervation in cancer: therapeutic implications
verfasst von
Atsunori Kamiya
Takeshi Hiyama
Atsushi Fujimura
Soichiro Yoshikawa
Publikationsdatum
14.09.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Autonomic Research / Ausgabe 2/2021
Print ISSN: 0959-9851
Elektronische ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-020-00724-y

Weitere Artikel der Ausgabe 2/2021

Clinical Autonomic Research 2/2021 Zur Ausgabe

Editorial

The Lovén reflex: the renaissance of a long-forgotten reflex involving autonomic and nociceptive pathways

Research Letter

Hypothalamic injury in spontaneous subarachnoid hemorrhage: a diffusion tensor imaging study

Research Article

The impact of endoscopic thoracic sympathectomy on sudomotor function in patients with palmar hyperhidrosis

Research Article

Inspiratory- and expiratory-gated transcutaneous vagus nerve stimulation have different effects on heart rate in healthy subjects: preliminary results

Editorial

Towards more evidenced-based therapies for postural tachycardia syndrome and other updates on recent autonomic research

Research Letter

A novel detrusor contractility parameter to distinguish multiple system atrophy from Parkinson’s disease

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Bildnachweise